NCT04627428: An ongoing trial by Luxa Biotechnology, LLC
This trial is ongoing. It must report results 1 year, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04627428 |
|---|---|
| Title | A Phase1/2a, Open-Label Study to Evaluate the Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation as Therapy for Dry Age-related Macular Degeneration (AMD) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 5, 2022 |
| Completion date | Dec. 1, 2026 |
| Required reporting date | Dec. 1, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |